{"id":880420,"date":"2026-09-05T02:50:27","date_gmt":"2026-09-05T02:50:27","guid":{"rendered":"https:\/\/www.newsbeep.com\/au\/880420\/"},"modified":"2026-09-05T02:50:27","modified_gmt":"2026-09-05T02:50:27","slug":"prostate-cancer-cardiovascular-risk-factors-may-help-identify-patients-who-would-benefit-from-additional-cardiac-care","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/au\/880420\/","title":{"rendered":"Prostate Cancer Cardiovascular Risk Factors May Help Identify Patients Who Would Benefit From Additional Cardiac Care"},"content":{"rendered":"

A set of uncontrolled, modifiable cardiovascular risk factors may help identify a subgroup of patients with prostate cancer who could benefit from additional cardiovascular care, according to findings published in\u00a0JACC: CardioOncology<\/a>\u00a0and presented at the ESC Congress 2026.\u00a0<\/p>\n

\u201cThe major findings from this stratified analysis of a large, pragmatic, international, randomized controlled trial of a structured cardiovascular intervention for patients with prostate cancer are that more favorable intervention estimates were observed among participants with total cholesterol >4 mmol\/L, self-reported hypertension or elevated baseline BP (systolic BP \u2265130 mm Hg or diastolic BP \u226580 mm Hg), and possibly diabetes,\u201d said\u00a0Cristina Cano Garcia, MD, and\u00a0Jehonathan Pinthus, MD, PhD, et al.<\/p>\n

RADICAL PC-2: Background and Study Methods\u00a0<\/p>\n

Researchers aimed to identify subgroups of patients with prostate cancer that are more likely to benefit from a referral for routine cardiovascular care.\u00a0<\/p>\n

The\u00a0RADICAL PC-2 (RAndomizeD Intervention for CArdiovascular and Lifestyle Risk Factors in Prostate Cancer Patients) study was a\u00a0pragmatic, randomized controlled trial looking at whether referral to a cardiologist or internist due to cardiovascular risk factors could improve outcomes for patients with newly diagnosed prostate cancer or those who were starting androgen-deprivation therapy for the first time (n = 2,487).\u00a0<\/p>\n

In the interventional group, patients were referred to a cardiologist or internist for statin therapy, blood pressure monitoring, lifestyle modification advice, smoking cessation, and more.<\/p>\n

The study looked at composite clinical outcomes including cardiovascular death, myocardial infarction, stroke, heart failure, suboptimal cholesterol, and systolic blood pressure control. The secondary outcome measure was time to cardiovascular death, myocardial infarction, stroke, or heart failure.\u00a0<\/p>\n

Follow-up was conducted at 3, 6, 12, 18, and 24 months, as well as annually thereafter through the end of the study.\u00a0<\/p>\n

Key Findings\u00a0<\/p>\n

The impact of treatment differed by patients’ baseline total cholesterol level of\u00a0\u22644 mmol\/L vs >4 mmol\/L (interaction\u00a0P\u00a0= .016).<\/p>\n

Additionally, treatment impact differed by baseline blood pressure status of\u00a0systolic blood pressure \u2265130 mm Hg or diastolic \u226580 mm Hg vs <130\/80 mm Hg; interaction\u00a0P\u00a0= .003).\u00a0In patients with a systolic\u00a0blood pressure\u00a0\u2265130 mm Hg or diastolic \u226580 mm Hg, the subdistribution hazard ratio (sHR) was 0.86 (95% confidence interval [CI] = 0.61\u20131.21), and 4.85 (95% CI = 1.65\u201314.26)\u00a0for those with a blood pressure\u00a0<130\/80 mm Hg.<\/p>\n

In a subgroup of patients with diabetes, the interaction\u00a0P-value did not reach statistical significance, although there was a numerical difference with sHRs of 0.53 (95% CI = 0.24\u20131.15) for patients with diabetes and 1.25 (95% CI = 0.88\u20131.78) for those without.\u00a0<\/p>\n

\u201cThis important international study works to establish an evidence base of who benefits and how they may benefit from cardiovascular and internist management of risk,\u201d added\u00a0Bonnie Ky, MD, MSCE, FACC, Editor-in-Chief of\u00a0JACC: CardioOncology.\u00a0<\/p>\n

DISCLOSURES: For full disclosures of the study authors, visit\u00a0jacc.org<\/a>.\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"A set of uncontrolled, modifiable cardiovascular risk factors may help identify a subgroup of patients with prostate cancer…\n","protected":false},"author":2,"featured_media":880421,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[64,63,137],"class_list":["post-880420","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-au","tag-australia","tag-health"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/880420","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/comments?post=880420"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/880420\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media\/880421"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media?parent=880420"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/categories?post=880420"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/tags?post=880420"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}